Shares of PTC Therapeutics took a hit this morning, dropping about 20% after the European Medicines Agency threw its considerable weight against the biotech’s application to gain a conditional approval for its Duchenne muscular dystrophy drug ataluren.

…read more

Source: PTC slammed after EMA spurns its bid for early OK of DMD drug


0 No comments